Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 18/20 | 0.73 |
| ▸ | DRD2 | P14416 | 16/20 | 0.73 |
| ▸ | HTR1A | P08908 | 3/20 | 0.50 |
| ▸ | DRD3 | P35462 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | DRD1 | P21728 | 1/20 | 0.47 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6206072 | 0.88 | HTR2A (0.68) | HTR2ADRD2HTR1A | |
| SCHEMBL6810810 | 0.86 | HTR2A (0.69) | HTR2ADRD2HTR1A | |
| SCHEMBL6205764 | 0.83 | HTR2A (0.62) | HTR2ADRD2HTR1A | |
| SCHEMBL6807595 | 0.81 | HTR2A (0.58) | HTR2ADRD2HTR1A | |
| SCHEMBL6816590 | 0.79 | HTR2A (0.54) | HTR2ADRD2HTR1A | |
| SCHEMBL6207690 | 0.77 | HTR2A (0.70) | HTR2ADRD2HTR1ADRD3CHRM2 | |
| SCHEMBL6190074 | 0.77 | HTR2A (0.67) | HTR2ADRD2HTR1ADRD3CHRM2 | |
| SCHEMBL6205715 | 0.77 | HTR2A (0.70) | HTR2ADRD2HTR1A | |
| SCHEMBL6185292 | 0.74 | HTR2A (1.00) | HTR2ADRD2HTR1ADRD3CHRM2 | |
| SCHEMBL6187950 | 0.74 | HTR2A (0.58) | HTR2ADRD2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040067960-A1 | Heterocyclic substituted piperazines for the treatment of schizophrenia | DAVIS JAMIE MARIE (US) | 2004-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067960-A1 | Heterocyclic substituted piperazines for the treatment of schizophrenia | HTR2C, CNR1, HTR2A | HTR2A 3/4885DRD2 4/4885HTR1A 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.